API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

6

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Clovis Oncology

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Clovis Enrolls First Patient in Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers

Details:

First patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib and Opdivo® (nivolumab) for the treatment of gynecologic cancers. The LIO-1 trial is part of Clovis Oncology’s broad clinical collaboration with Bristol Myers Squibb.

Lead Product(s): Lucitanib,Nivolumab

Therapeutic Area: Oncology Product Name: CO-3810

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Bristol Myers Squibb

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

ASK
US

Upload
your Marketing & Sales content

Alkermes Plc

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 AACR Virtual Annual Meeting II

Details:

The study evaluated the antitumor efficacy and mechanism of action of mALKS 4230, a mouse ortholog of ALKS 4230, and lucitanib as monotherapies and in combination in a preclinical syngeneic mouse model of colon cancer.

Lead Product(s): ALKS 4230,Lucitanib

Therapeutic Area: Oncology Product Name: ALKS 4230

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Colvis Oncology

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

ASK
US

Upload
your Marketing & Sales content

Clovis Oncology

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020

Details:

Findings explore the pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of Rubraca and lucitanib alone and in combination with other agents in preclinical models and simulated patient populations.

Lead Product(s): Lucitanib,ALKS 4230

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

ASK
US

Upload
your Marketing & Sales content